tiprankstipranks
Advertisement
Advertisement

MedPlus Subsidiary Faces Two-Day Drug License Suspension at Karnataka Store

Story Highlights
  • MedPlus unit Optival Health had a Karnataka store’s drug license suspended for two days.
  • The isolated suspension may cost about Rs 2.88 lakh and highlights regulatory scrutiny and compliance needs.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
MedPlus Subsidiary Faces Two-Day Drug License Suspension at Karnataka Store

Claim 55% Off TipRanks

MedPlus Health Services Ltd. ( (IN:MEDPLUS) ) has issued an update.

MedPlus Health Services Ltd. disclosed that its subsidiary, Optival Health Solutions, has received a two-day suspension of a drug license for one of its stores located at Bidadi Bus Stand in Karnataka. The suspension was ordered by the Assistant Director of the Drugs Control Administration, Bangalore South Circle, under Rule 65 of the Drugs and Cosmetics Act, 1940, and corresponding Rules of 1945, resulting in an estimated potential revenue loss of Rs 2.88 lakh but affecting only a single outlet in its wider network.

The company has indicated that details of the regulatory action will be made available on its website and on the stock exchanges where its shares are listed. While the monetary impact appears limited and confined to one store, the incident underscores ongoing regulatory scrutiny in the pharmaceutical retail sector and highlights the importance of strict compliance with drug licensing norms for MedPlus and its subsidiaries.

More about MedPlus Health Services Ltd.

MedPlus Health Services Ltd. is a pharmacy retail and healthcare services company operating through a network of stores across India. Its subsidiary Optival Health Solutions Private Limited manages retail outlets that dispense pharmaceutical products, health supplies, and related services, with a strong presence in states including Karnataka.

Average Trading Volume: 17,362

Technical Sentiment Signal: Strong Buy

Current Market Cap: 102.3B INR

For an in-depth examination of MEDPLUS stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1